Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke

Tissue Plasminogen Activator Stroke Study

Steven R. Levine
Edward C. Jauch
Christopher Lindsell
Joseph Broderick
Susan C. Fagan
Barbara C. Tilley
Susan C. Fagan
Pharmd Barbara
C. Tilley
Phd Steven
R. Levine

January 2006

The online version of this article, along with updated information and services, is located on th

Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial

Vicki S. Hertzberg
Thomas Arthur Louis
Teresa J. Hengy
Timothy John Ingall
William Michael O’fallon
Kjell Asplund
Lewis Robert
Timothy John
Ingall Mb
Phd William
Thomas Arthur Louis
Phd Teresa J. Hengy Christianson

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

Stroke Outcome in Patients Treated With Tissue

Robert A. Felberg

December 2014

The online version of this article, along with updated information and services, is located on th

Adding to the effectiveness of intravenous tissue plasminogen activator for treating acute stroke

James C. Grotta
James C. Grotta

February 2015

The online version of this article, along with updated information and services, is located on th

Good Outcomes in Ischemic Stroke Patients Treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms

Adrian M. Siegel
Dimitrios Georgiadis
Christian R. Baumann
Ralf W. Baumgartner
Joubin G
Hans-christian Von Büdingen

March 2015

The online version of this article, along with updated information and services, is located on th

Quality improvement and tissue-type plasminogen activator for acute ischemic stroke-a Cleveland update. Stroke

Irene L. Katzan
Maxim D. Hammer
Anthony J. Furlan
Eric D. Hixson
Deborah M
A Cleveland Update

January 2003

The online version of this article, along with updated information and services, is located on th

Predicting improvement in gait after stroke

Boudewijn Kollen
Ingrid Van De Port
Eline Lindeman
Jos Twisk
Gert Kwakkel
Jos Twisk
Phd Gert Kwakkel

January 2005

The online version of this article, along with updated information and services, is located on th

Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like

Nadine Wilczak
Jan Willem Elting
Daniel Chesik
Ido P. Kema
Jacques De Keyser
Nadine Wilczak
Phd Jan
Willem Elting
Md Daniel Chesik
Ido P. Kema
Md Jacques
De Keyser

August 2015

The online version of this article, along with updated information and services, is located on th

Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window

Elisenda Grivé
Juan F. Arenillas
José Álvarez-sabín
Marc Ribo
Carlos A. Molina
Alex Rovira
Manuel Quintana
Pilar Delgado
Joan Montaner
Using Multimodal

January 2005

The online version of this article, along with updated information and services, is located on th

Monitoring Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke With

Olivia Pohlers
Henning Ryssel
Klaus Sartor
Werner Hacke
Peter D. Schellinger
Olav Jansen
Jochen B. Fiebach
Sabine Heil
Thorsten Steiner

January 2015

The online version of this article, along with updated information and services, is located on th

Favorable Outcome of Ischemic Stroke in Patients

Robert Belvís
Dolores Cocho
Jaume Roquer
Ana Rodríguez
María Dolores García
Joan Martí-fàbregas
Meritxell Gomis
Adrià Arboix
Aitziber Aleu
Javier Pagonabarraga
Pretreated Statins

January 2004

The online version of this article, along with updated information and services, is located on th

Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals

Shelby D. Reed
Steven C. Cramer
David K. Blough
Kerry Meyer
Jeffrey G. Jarvik
Shelby D. Reed
Phd Steven
C. Cramer
Md David
K. Blough
Kerry Meyer
Phd Jeffrey
G. Jarvik

January 2001

The online version of this article, along with updated information and services, is located on th

Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy

Christopher J. Weir
Markku Kaste
Kennedy R. Lees
Christopher J. Weir
Phd Markku Kaste
Md Kennedy
R. Lees
Frcp For The Glycine

January 2004

The online version of this article, along with updated information and services, is located on th

Current indications and results of thrombolysis by intravenous recombinant tissue plasminogen activator.

Francesca Tari Capone
Michele Cavallari
Barbara Casolla
Francesco Orzi

January 2012

A number of landmark trials have proven the efficacy of thrombolysis by intravenous recombinant tiss...

Outcome After Thrombolytic Treatment in Acute Stroke

Antonio Dávalos
Iván Cristobo
María M. García
José Vivancos
Joaquín Serena
María A. Moro
Mónica Millan
Tomás Sobrino
Mar Castellanos
Florentino Nombela
Juan F. Arenillas

August 2015

The online version of this article, along with updated information and services, is located on th

Tissue Plasminogen Activator Stroke Study

Steven R. Levine
Edward C. Jauch
Christopher Lindsell
Joseph Broderick
Susan C. Fagan
Barbara C. Tilley
Susan C. Fagan
Pharmd Barbara
C. Tilley
Phd Steven
R. Levine

January 2006

The online version of this article, along with updated information and services, is located on th

Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial

Vicki S. Hertzberg
Thomas Arthur Louis
Teresa J. Hengy
Timothy John Ingall
William Michael O’fallon
Kjell Asplund
Lewis Robert
Timothy John
Ingall Mb
Phd William
Thomas Arthur Louis
Phd Teresa J. Hengy Christianson

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

Stroke Outcome in Patients Treated With Tissue

Robert A. Felberg

December 2014

The online version of this article, along with updated information and services, is located on th

Adding to the effectiveness of intravenous tissue plasminogen activator for treating acute stroke

James C. Grotta
James C. Grotta

February 2015

The online version of this article, along with updated information and services, is located on th

Good Outcomes in Ischemic Stroke Patients Treated With Intravenous Thrombolysis Despite Regressing Neurological Symptoms

Adrian M. Siegel
Dimitrios Georgiadis
Christian R. Baumann
Ralf W. Baumgartner
Joubin G
Hans-christian Von Büdingen

March 2015

The online version of this article, along with updated information and services, is located on th

Quality improvement and tissue-type plasminogen activator for acute ischemic stroke-a Cleveland update. Stroke

Irene L. Katzan
Maxim D. Hammer
Anthony J. Furlan
Eric D. Hixson
Deborah M
A Cleveland Update

January 2003

The online version of this article, along with updated information and services, is located on th

Predicting improvement in gait after stroke

Boudewijn Kollen
Ingrid Van De Port
Eline Lindeman
Jos Twisk
Gert Kwakkel
Jos Twisk
Phd Gert Kwakkel

January 2005

The online version of this article, along with updated information and services, is located on th

Intravenous Tissue Plasminogen Activator in Patients With Stroke Increases the Bioavailability of Insulin-Like

Nadine Wilczak
Jan Willem Elting
Daniel Chesik
Ido P. Kema
Jacques De Keyser
Nadine Wilczak
Phd Jan
Willem Elting
Md Daniel Chesik
Ido P. Kema
Md Jacques
De Keyser

August 2015

The online version of this article, along with updated information and services, is located on th

Safety and Efficacy of Intravenous Tissue Plasminogen Activator Stroke Treatment in the 3- to 6-Hour Window

Elisenda Grivé
Juan F. Arenillas
José Álvarez-sabín
Marc Ribo
Carlos A. Molina
Alex Rovira
Manuel Quintana
Pilar Delgado
Joan Montaner
Using Multimodal

January 2005

The online version of this article, along with updated information and services, is located on th

Monitoring Intravenous Recombinant Tissue Plasminogen Activator Thrombolysis for Acute Ischemic Stroke With

Olivia Pohlers
Henning Ryssel
Klaus Sartor
Werner Hacke
Peter D. Schellinger
Olav Jansen
Jochen B. Fiebach
Sabine Heil
Thorsten Steiner

January 2015

The online version of this article, along with updated information and services, is located on th

Favorable Outcome of Ischemic Stroke in Patients

Robert Belvís
Dolores Cocho
Jaume Roquer
Ana Rodríguez
María Dolores García
Joan Martí-fàbregas
Meritxell Gomis
Adrià Arboix
Aitziber Aleu
Javier Pagonabarraga
Pretreated Statins

January 2004

The online version of this article, along with updated information and services, is located on th

Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals

Shelby D. Reed
Steven C. Cramer
David K. Blough
Kerry Meyer
Jeffrey G. Jarvik
Shelby D. Reed
Phd Steven
C. Cramer
Md David
K. Blough
Kerry Meyer
Phd Jeffrey
G. Jarvik

January 2001

The online version of this article, along with updated information and services, is located on th

Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy

Christopher J. Weir
Markku Kaste
Kennedy R. Lees
Christopher J. Weir
Phd Markku Kaste
Md Kennedy
R. Lees
Frcp For The Glycine

January 2004

The online version of this article, along with updated information and services, is located on th

Current indications and results of thrombolysis by intravenous recombinant tissue plasminogen activator.

Francesca Tari Capone
Michele Cavallari
Barbara Casolla
Francesco Orzi

January 2012

A number of landmark trials have proven the efficacy of thrombolysis by intravenous recombinant tiss...

Outcome After Thrombolytic Treatment in Acute Stroke

Antonio Dávalos
Iván Cristobo
María M. García
José Vivancos
Joaquín Serena
María A. Moro
Mónica Millan
Tomás Sobrino
Mar Castellanos
Florentino Nombela
Juan F. Arenillas

August 2015

The online version of this article, along with updated information and services, is located on th

Tissue Plasminogen Activator Stroke Study

Steven R. Levine
Edward C. Jauch
Christopher Lindsell
Joseph Broderick
Susan C. Fagan
Barbara C. Tilley
Susan C. Fagan
Pharmd Barbara
C. Tilley
Phd Steven
R. Levine

January 2006

The online version of this article, along with updated information and services, is located on th

Findings From the Reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment Trial

Vicki S. Hertzberg
Thomas Arthur Louis
Teresa J. Hengy
Timothy John Ingall
William Michael O’fallon
Kjell Asplund
Lewis Robert
Timothy John
Ingall Mb
Phd William
Thomas Arthur Louis
Phd Teresa J. Hengy Christianson

January 2004

located on the World Wide Web at: The online version of this article, along with updated information...

Stroke Outcome in Patients Treated With Tissue

Robert A. Felberg

December 2014

The online version of this article, along with updated information and services, is located on th

Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke

Abstract

Extracted data

Predicting major neurological improvement with intravenous recombinant tissue plasminogen activator treatment of stroke

Abstract

Extracted data

Related items

Related items